Fresenius Medical Care
About: Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
Employees: 111,513
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
171% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 14
117% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $602K
47% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 43
13% more funds holding
Funds holding: 165 [Q3] → 187 (+22) [Q4]
8% more capital invested
Capital invested by funds: $713M [Q3] → $770M (+$56.9M) [Q4]
0.19% more ownership
Funds ownership: 11.41% [Q3] → 11.59% (+0.19%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for FMS.
Financial journalist opinion
Based on 20 articles about FMS published over the past 30 days
